CGMs & Non-Insulin-Treated T2D, Islet Autoantibody Screening & T1D, Semaglutide CVD Risk Reduction, and more!

0:00-31:52

Welcome to the latest episode (November 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Oser, et al. Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes. New England Journal of Medicine. October 2026; doi.org/10.1056/NEJMoa2608571 Islet autoantibody screening identifies early-stage type 1 diabetes across Europe, Need-To-Know Institute press release Yang, et al. Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis. JAMA. Published online October 2026. doi.org/10.1001/jama.2026.19921 Jastreboff, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. September, 2026. doi.org/10.1056/NEJMoa2604169 Bellido, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. Volume 408, Issue 10563. doi.org/10.1016/S0140-6736(26)01861-1 Colhoun, et al. Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial. European Heart Journal. 2026; ehag524, doi.org/10.1093/eurheartj/ehag524 Garvey, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.

Publisher

DOC Updates

Link

diabetescoreupdate.libsyn.com/cgms-non-insulin-treated-t2d-islet-autoantibody-screening-t1d-semaglutide-cvd-risk-reduction-and-more

Published

October 29, 2026

Duration

32 min

Format

Podcast

Category

Lifestyle · Medicine

Source

RSS feed

Host

American Diabetes Association

DU

DOC Updates

@docupdates

#treatedt2d #isletautoantibodyscreening #semaglutidecvdrisk #medicine

The Nile